Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bazedoxifene - A New Selective Estrogen Receptor Modulator Treatment for Women With Schizophrenia: a Double-blind, Randomized, Placebo Controlled Trial

NCT04113993 is registered in ClinicalTrials.gov with The Alfred as lead sponsor.

NCT NCT04113993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04113993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bazedoxifene - A New Selective Estrogen Receptor Modulator Treatment for Women With Schizophrenia: a Double-blind, Randomized, Placebo Controlled Trial
Lead sponsor
The Alfred
Phase
Phase 4
Overall status
Recruiting
Start date
October 7, 2019
Completion date
December 31, 2026
Enrollment
160 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizo affective disorder, schizophrenia, schizophreniform disorders